The biotech company is seeking up to $45m from an initial public offering that will be conducted in April or May 2017, and is currently raising more funding.
Promethera Biosciences, a Belgium-based liver disease treatment developer backed by pharmaceutical company Boehringer Ingelheim, has begun preparations for an initial public offering in April or May 2017, Le Soir reported on Tuesday.
Promethera, which also counts construction firm SMS Group, drugs company Shire, conglomerate Mitsui and bioprocess systems manufacturer ATMI as investors, is targeting between €30m and €40m ($34m and $45m) in the offering.
The company also revealed it is in process of raising €6m to €10m in funding from…
